1
General Information
Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection.
It is developing a range of blood-based cancer screening tests.
2
Freenome (FRNM) Stock Graph
3
How We Grade Freenome (FRNM)
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade Freenome (FRNM) across the board compared to its closest peers.
4
Benzinga Edge Rankings
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
5
Peer Ratings
See how Freenome compares to its peers in these key performance metrics from Benzinga Rankings.
Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
VORVor Biopharma
N/A
N/A
N/A
79.05
ALVOAlvotech
25.11
N/A
N/A
71.86
AKTSAktis Oncology
N/A
N/A
N/A
N/A
PURRHyperliquid Strategies
N/A
N/A
N/A
N/A
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on an aggregation of 0 analyst ratings over the past 3 months and their 12-month price targets.
Below, you can see that analysts are estimating a 12-month price target range of $17.00 - $18.00 with an average of $17.33
34.89%
Expected movement for Freenome (FRNM) over the next 12 months
Based on these rankings
Recent Ratings for Freenome (FRNM)
